Intelligence · Clinical Development
Pipeline search results
Programs matching “cisplatin” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 56 pipeline programs matching "cisplatin" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
CMUH-HO-NPC001
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Head and Neck Carcinoma
1 trial -
Camrelizumab with vinorelbine and cisplatin
The First People's Hospital of Lianyungang
HER2-negative Breast Cancer
1 trial -
Capecitabine+Cisplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stomach Neoplasms
1 trial -
Cisplatin
Ultragenyx UK Limited
Squamous Cell Carcinoma of the Anus
1 trial -
Cisplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cervical Cancer
1 trial -
Cisplatin Accord Healthcare /ml concentraat v... for Vulvar cancer
Disc Medicine
Vulvar cancer
1 trial -
Cisplatin and Doxorubicin
Chinese University of Hong Kong
Gastric Cancer Peritoneal Metastases
1 trial -
Cisplatin+Capecitabine+Sintilimab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
FEMH-95011
Hospital Authority, Hong Kong
Stomach Neoplasms
1 trial -
Gemcitabine plus Cisplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Biliary Tract Cancer
1 trial -
Gemcitabine/Cisplatin
BRIGHT MINDS BIOSCIENCES INC.
Upper Tract Urothelial Carcinoma
1 trial -
Injection of IAH0968+Gemcitabine+Cisplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HER2 Gene Mutation
1 trial -
Karelizumab combined with etoposide and cisplatin
Jian Li
Carcinoma
1 trial -
TAX625
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Advanced Breast Cancer
1 trial -
TS-1 with cisplatin
Hospital Authority, Hong Kong
Recurrent Gastric Cancer
1 trial -
Trastuzumab in Combination with TS-ONE and cisplatin
Hospital Authority, Hong Kong
Gastric Cancer
1 trial -
anlotinib+TQB2450+nab-paclitaxel+cisplatin
The First People's Hospital of Lianyungang
Advanced Biliary Tract Cancer
1 trial -
cisplatin
Cardiff Oncology
Bladder Cancer
2 trials -
cisplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Esophageal Squamous Cell Carcinoma
1 trial -
cisplatin and 5-Fu combined with nimotuzumab
The First People's Hospital of Lianyungang
Stage IV Nasopharyngeal Carcinoma
1 trial -
gemcitabine and cisplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Squamous Cell Carcinoma
1 trial -
genexolPM + cisplatin
Solid Biosciences
Locally Advanced Head and Neck Squamous Cell Carcinoma
1 trial -
Cisplatin
BioMarin Pharmaceutical Australia Pty Ltd
Solid Tumors
1 trial -
Cisplatin
Regeneron UK Limited
Head and Neck Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.